IRIC

2 octobre 2026

EZH2 Inhibition Induces a Metabolic Stress Response Sensitizing Triple-Negative Breast Cancer to Glutaminase Targeting.

Porras L, Carrière M, Gironne AS, Philippeau H, Alzial G, Quadri E, Cormery J, Alaessa Y, Monast A, Gorse F, St-Arnaud M, De Sa Tavares Russo M, Mader S, Avizonis DZ, Lemieux S, Park M, Deblois G
Cancer Res 2026-10-02 ;

11 septembre 2026

Mice with the mono-allelic p.R37H Dhdds variant show aberrant glycosylation and interneuron deficits.

Da Silva A, Fallah MS, Tene Tadoum SB, Fazeli M, Muffels IJJ, Wang S, Grenier F, Budhraja R, Sturiale L, Messina A, Giladi M, Taherzadeh M, Bonneil E, Khan S, Vruchte DT, Yamanaka Y, Di Cristo G, Hamdan FF, Platt FM, Tomatsu S, Haitin Y, Kozicz T, Thibault P, Garozzo D, Pandey A, Morava E, Rossignol E, Pshezhetsky AV
Brain 2026-09-11 ;

31 août 2026

Lysyl oxidase inhibition disrupts mitochondrial homeostasis to create vulnerability to ferroptosis in TNBC.

Saatci O, Ulukan B, Cetin M, Kuasne H, Martinez C, Percin E, Oleinik N, Savoca MT, Nehme A, Hernández-Corchado A, Zavacky E, Sreenivas K, Rezaeian AH, Bethard JR, Anoma JS, Sahin OS, Aguilar-Mahecha A, Buchanan M, Aras M, DeBlois G, Basik M, Hill EG, Ball LE, Rao CN, McInnes C, Riazalhosseini Y, Najafabadi HS, Lemasters JJ, Ogretmen B, Park M, Sahin O
Cell Rep Med 2026-08-31 ;7( 9 ):103015

28 août 2026

The structure of the dopamine D₃ receptor bound to cariprazine reveals principles for partial agonists with designed pharmacology.

Hadas Yardeni E, Kiss DJ, Sanchez J, Shavit K, Szepesi Kovács D, Egyed A, Vogt CD, Gaitonde SA, Glenn J, Canals M, Bouvier M, Newman AH, Lane JR, Keserű GM, Shalev-Benami M
Sci Adv 2026-08-28 ;12( 35 ):eaef7411

22 août 2026

BiDRA: Bayesian inference as a robust alternative to non-linear regression for dose-response efficiency metrics assessment.

Labelle C, Smirnov P, David M, Callejo M, Haibe-Kains B, Marinier A, Lemieux S
Bioinform Adv 2026-08-22 ;6( 1 ):vbag245

18 août 2026

Modeling KRAS mutations in KMT2A::MLLT3 acute myeloid leukemia promotes leukemic progression and transcriptional rewiring.

Esparza N, Defrêne J, Bresson E, Soufflet AC, Juárez-Rodríguez MM, Lisi V, Hernández-Sánchez A, Bullinger L, Lavallée VP, Wilhelm B, Barabé F
Leukemia 2026-08-18 ;

5 août 2026

A distinctive PDZ:β-hairpin interaction mediates AFDN complex with SCRIB and promotes binding to KRAS.

Jo CH, Strakhova R, Goudreault M, Bernal Astrain G, Smith M
Biochem J 2026-08-05 ;483( 8 ):1575-1589

4 août 2026

Invariant chain controls HLA-DQ folding and shapes the HLA class II proxiome.

Moulefera MA, Mitchell W, Bilali NE, Majdoubi A, Panès R, Salti S, Lippé R, Gagnon E, Mourad W, Thibodeau J
J Immunol 2026-08-04 ;215( 8 ):

IRIC – Institut de recherche en immunologie et en cancérologie de l’Université de Montréal

Publications

Publications récentes

EZH2 Inhibition Induces a Metabolic Stress Response Sensitizing Triple-Negative Breast Cancer to Glutaminase Targeting.

Mice with the mono-allelic p.R37H Dhdds variant show aberrant glycosylation and interneuron deficits.

Lysyl oxidase inhibition disrupts mitochondrial homeostasis to create vulnerability to ferroptosis in TNBC.

The structure of the dopamine D₃ receptor bound to cariprazine reveals principles for partial agonists with designed pharmacology.

BiDRA: Bayesian inference as a robust alternative to non-linear regression for dose-response efficiency metrics assessment.

Modeling KRAS mutations in KMT2A::MLLT3 acute myeloid leukemia promotes leukemic progression and transcriptional rewiring.

A distinctive PDZ:β-hairpin interaction mediates AFDN complex with SCRIB and promotes binding to KRAS.

Invariant chain controls HLA-DQ folding and shapes the HLA class II proxiome.

Publications

EZH2 Inhibition Induces a Metabolic Stress Response Sensitizing Triple-Negative Breast Cancer to Glutaminase Targeting.

Mice with the mono-allelic p.R37H Dhdds variant show aberrant glycosylation and interneuron deficits.

Lysyl oxidase inhibition disrupts mitochondrial homeostasis to create vulnerability to ferroptosis in TNBC.

The structure of the dopamine D3 receptor bound to cariprazine reveals principles for partial agonists with designed pharmacology.

BiDRA: Bayesian inference as a robust alternative to non-linear regression for dose-response efficiency metrics assessment.

Modeling KRAS mutations in KMT2A::MLLT3 acute myeloid leukemia promotes leukemic progression and transcriptional rewiring.

A distinctive PDZ:β-hairpin interaction mediates AFDN complex with SCRIB and promotes binding to KRAS.

Invariant chain controls HLA-DQ folding and shapes the HLA class II proxiome.

The structure of the dopamine D₃ receptor bound to cariprazine reveals principles for partial agonists with designed pharmacology.